231 related articles for article (PubMed ID: 28764837)
1. Supportive Treatments for Patients with Cancer.
Jordan K; Feyer P; Höller U; Link H; Wörmann B; Jahn F
Dtsch Arztebl Int; 2017 Jul; 114(27-28):481-487. PubMed ID: 28764837
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
[TBL] [Abstract][Full Text] [Related]
5. Managing Nausea and Vomiting in Patients With Cancer: What Works.
Navari RM
Oncology (Williston Park); 2018 Mar; 32(3):121-5, 131, 136. PubMed ID: 29548068
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
7. Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse.
Houston D
Cancer Nurs; 1997 Dec; 20(6):409-13. PubMed ID: 9409062
[TBL] [Abstract][Full Text] [Related]
8. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
9. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
11. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
12. [Supportive therapy in medical therapy of head and neck tumors].
Link H
Laryngorhinootologie; 2012 Mar; 91 Suppl 1():S151-75. PubMed ID: 22456916
[TBL] [Abstract][Full Text] [Related]
13. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.
Adamo V; Antonuzzo L; Danova M; De Laurentiis M; Marchetti P; Pinto C; Rosti G
Support Care Cancer; 2022 Dec; 30(12):9877-9888. PubMed ID: 36334157
[TBL] [Abstract][Full Text] [Related]
14. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Scotté F; Schwartzberg L; Iihara H; Aapro M; Gralla R; Hesketh PJ; Jordan K; Chow R; Herrstedt J
Support Care Cancer; 2023 Dec; 32(1):45. PubMed ID: 38114821
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery).
Vayne-Bossert P; Haywood A; Good P; Khan S; Rickett K; Hardy JR
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012002. PubMed ID: 28671265
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
18. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
19. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
